Filing Flows › Comparisons › GERN vs AGIO
Geron vs Agios Pharmaceuticals: GERN and AGIO compared
Geron is the larger company: $60.2M of revenue in its latest quarter (Q3 2026) against $55.4M for Agios Pharmaceuticals (Q3 2026). Agios Pharmaceuticals is growing faster (+330% against +27% a year earlier). Geron is more profitable, with an operating margin of 9.6% against -139.3%.
Where the money goes: GERN and AGIO
Geron (GERN) · Q3 2026
Geron, Q3 2026: revenue $60.2M (+27% year over year), operating margin 9.6%, net earnings $1.4M, operating cash flow $10.3M. The chart follows the revenue to costs, profit and cash.
Agios Pharmaceuticals (AGIO) · Q3 2026
Agios Pharmaceuticals, Q3 2026: revenue $55.4M (+330% year over year), operating margin -139.3%, net loss $65.0M, operating cash flow −$59.2M. The chart follows the revenue to costs, profit and cash.
| Geron (GERN) | Agios Pharmaceuticals (AGIO) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $60.2M | $55.4M |
| Revenue growth, Y/Y | +27% | +330% |
| Operating margin | 9.6% | -139.3% |
| Net earnings | $1.4M | −$65.0M |
| Net margin | 2.2% | -117.4% |
| Operating cash flow | $10.3M | −$59.2M |
| Market value | — | $1.9B |
| Analysts’ mean target | — | $45.88 |
Questions
Which is bigger, Geron or Agios Pharmaceuticals?
Geron is the larger company: $60.2M of revenue in its latest quarter (Q3 2026) against $55.4M for Agios Pharmaceuticals (Q3 2026).
Is Geron or Agios Pharmaceuticals growing faster?
Agios Pharmaceuticals is growing faster (+330% against +27% a year earlier).
Which is more profitable, Geron or Agios Pharmaceuticals?
Geron is more profitable, with an operating margin of 9.6% against -139.3%.
More: Geron earnings · how Geron makes money · Agios Pharmaceuticals earnings · how Agios Pharmaceuticals makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 4, 2026; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.